Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Quinacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.96 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.96 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.96 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.96 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.96 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.96 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.96 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.96 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.96 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.96 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.96 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.96 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.96 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.96 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.96 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.96 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.96 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinacrine SCHEMBL25334547 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL450737 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL7147117 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL162378 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL30416460 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL28651594 | 0.99 | USP2 (0.98) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL30153780 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL162379 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL15061349 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL33693 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360124-A1 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2025-11-27 | — | — | US | disclosed |
| EP-4536641-A1 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2025-04-16 | — | — | EP | disclosed |
| CN-119403788-A | Novel RAS inhibitors | KHR生物技术有限公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2023242105-A9 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2025-01-02 | — | — | WO | disclosed |
| WO-2023242105-A1 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2023-12-21 | — | — | WO | disclosed |
| EP-0483249-B1 | METHOD OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION AND OF DISCOVERING CHEMICALS CAPABLE OF FUNCTIONING AS GENE EXPRESSION MODULATORS | OSI PHARM INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6376175-B1 | CONTACTING CELL WHICH IS CAPABLE OF EXPRESSING GENE WITH AMOUNT OF MOLECULE EFFECTIVE TO TRANSCRIPTIONALLY MODULATE EXPRESSION OF GENE AND THEREBY AFFECT LEVEL OF PROTEIN ENCODED BY GENE WHICH IS EXPRESSED BY CELL | OSI PHARMACEUTICALS, INC. | 2002-04-23 | — | — | US | disclosed |
| US-6203976-B1 | DRUG SCREENING USING EUKARYOTIC CELLS WITH DNA CONSTRUCT OF REGULATORY SEQUENCE AND PROMOTER LINKED TO REPORTER GENE, CONTACTING WITH CHEMICAL, QUANTITATIVELY DETERMINING SIGNAL PRODUCED, COMPARING TO CONTROLS, THEN MIXING WITH CARRIER | OSI PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| US-5665543-A | Method of discovering chemicals capable of functioning as gene expression modulators | ONCOGENE SCIENCE, INC. (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0483249-A4 | — | — | 1994-04-06 | — | — | EP | disclosed |
| WO-1992012635-A1 | METHODS OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION OF VIRAL GENES AND OTHER GENES | ONCOGENE SCIENCE, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| WO-1992013092-A1 | METHODS OF TRANSCRIPTIONALLY MODULATING EXPRESSION OF HEMATOPOIETIC GROWTH FACTOR GENES | ONCOGENE SCIENCE, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| WO-1992013063-A1 | METHODS OF TRANSCRIPTIONALLY MODULATING EXPRESSION OF GROWTH FACTOR GENES AND GROWTH FACTOR RECEPTOR GENES | ONCOGENE SCIENCE, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0483249-A1 | METHOD OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION AND OF DISCOVERING CHEMICALS CAPABLE OF FUNCTIONING AS GENE EXPRESSION MODULATORS | Oncogene Science, Inc. (US) | 1992-05-06 | — | — | EP | disclosed |
| WO-1991001379-A1 | METHOD OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION AND OF DISCOVERING CHEMICALS CAPABLE OF FUNCTIONING AS GENE EXPRESSION MODULATORS | ONCOGENE SCIENCE, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360124-A1 | NOVEL RAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4794/4885CHRM4 4872/4885HTR1A 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.